Summary. Zebrafish were used as a model to study haemostasis, a vertebrate function of paramount importance. A limitation of the zebrafish model is the difficulty in assaying small amounts of blood to detect coagulation mutants. We report the use of a rapid total coagulation activity (TCA) assay to screen for coagulation defects in individual adult zebrafish. We screened the TCA in 1000 gynogenetic half-tetrad diploids derived from 86 clutches. Each clutch was from a single F1 female offspring of males mutagenized with ethylnitrosourea (ENU). We found 30± 50% defective zebrafish among six clutches, consistent with a heritable defect. The assay developed here provided a rapid screen to detect overall coagulation defects. However, because of the limited amounts of plasma, we could not detect defects in specific pathways. Therefore, a novel, ultrasensitive kinetic method was developed to identify specific pathway defects. To test whether the kinetic assay could be used as a screening tool, 1500 Florida wild-type zebrafish pairs were analysed for naturally occurring coagulation defects. We detected 30 fish with extrinsic pathway defects, but with intact common and intrinsic pathways. We conclude that it is now possible to identify specific coagulation pathway defects in zebrafish.
In mammals, blood coagulation is initiated when exposed tissue factor on the subendothelial surface binds to the preexisting factor VIIa and cleaves factor X to Xa, which then converts prothrombin to thrombin. The small amount of thrombin generated by this initiation pathway (also called the extrinsic pathway) then activates factor XI to XIa. The XIa cleaves factor IX to generate active factor IXa, which converts more of factor X to Xa, thus converting large amounts of prothrombin to thrombin. The excess thrombin then cleaves enormous quantities of fibrinogen to generate fibrin. This propagation pathway, when measured in vitro by contact activation of factor XII to XIIa, which cleaves factor XI to XIa, is termed the intrinsic pathway. As factor Xa activation of prothrombin and conversion of fibrinogen to fibrin are common to both pathways, this is called the common pathway. Factor Xa and IXa require cofactors Va and VIIIa, respectively, which are generated from their precursors by cleavage with thrombin (Mann, 1999) . Despite the extensive biochemical characterization of mammalian blood coagulation in vitro, little is known about coagulation in vivo. For example, the mechanisms of initial activation of pre-existing factor VIIa are still elusive. As these problems are exceptionally difficult to approach in the mammalian system, new genetic approaches, similar to those used in Escherichia coli, Drosophila melanogaster and Caenorhabditis elegans, are essential for understanding these unresolved pathways.
To address these issues in blood coagulation and haemostasis, we have turned to the zebrafish model because it is an important genetic model to identify unknown functions of vertebrate genes (Amatruda & Zon, 1999; Fishman, 1999) . We hypothesized that the genetic power of the zebrafish model could be harnessed to study haemostasis (Jagadeeswaran & Liu, 1997a,b; Jagadeeswaran et al, 1999a) . Given the size of the zebrafish, the currently available methods to assay coagulation activities are unsuitable and an assay that can detect total coagulation activity (TCA) (from all pathways) in microquantities of zebrafish plasma is not available, but is essential for screening individual zebrafish mutants. Likewise, the assays to measure individual pathways of blood coagulation from a single zebrafish, which are crucial to assign the mutants to respective pathways, are not available.
In this paper, we report screening of ethylnitrosurea (ENU)-mutagenized zebrafish using a novel TCA screening assay to identify six zebrafish clutches with defects in thrombin formation. To characterize these mutants further and to evaluate coagulation from individual zebrafish, we developed a novel ultra-sensitive kinetic method and validated it with human normal and coagulation factordeficient plasmas. We used the later assay to screen a wildtype zebrafish population and identified background mutations/polymorphisms in extrinsic pathway activities. Our report is the first to apply classical genetic methods to the coagulation process and demonstrates the feasibility of using the zebrafish model to study haemostasis. Furthermore, the assays developed here may find applications in haemostasis studies in other small animal models and humans and may be useful in screening for anti-thrombotic drugs in zebrafish.
MATERIALS AND METHODS

Materials.
Pooled normal (Dade Ci-Trol level I) and coagulation factor-deficient (Dade) human plasmas, rabbit brain thromboplastin (Dade Thromboplastin C Plus) and rabbit brain partial thromboplastin reagent containing ellagic acid (Dade Actin) were obtained from Baxter Diagnostics (Deerfield, IL, USA). The purified factor X activator from Russell viper venom (RVV)-Xa, Protac (purified protein C activator from Agkistrodon contortrix venom) and corn trypsin inhibitor (CTI) were purchased from Hematologic Technologies (Essex Junction, VT, USA). Recombinant hirudin, unfractionated porcine heparin, low molecular weight heparin, sodium warfarin and bovine serum albumin (fraction V) were purchased from Sigma Chemical (St. Louis, MO, USA). Tick anticoagulant protein (TAP) was a gift from George Vlasuk (Corvas International). Bio-Rad Protein Assay Dye Reagent Concentrate was from Bio-Rad Laboratories (Hercules, CA, USA). Human plasma fibrinogen was purchased from Calbiochem (LaJolla, CA, USA). All other chemicals were at least reagent grade and purchased from major suppliers.
Zebrafish. Florida wild-type zebrafish were purchased from Ekkwill Tropical Fish Farm (Gibsonton, FL, USA) and kept in the conditions previously described (Jagadeeswaran & Liu, 1997a) . Briefly, zebrafish were kept in 20 gallon tanks with deionized water containing 60 mg of Instant Ocean (Lone Star, San Antonio, TX, USA) per litre. The water was constantly recirculated through biological filters and treated with ultraviolet (UV) light. Young adult fish (approximately 3 cm in length) were used for these studies. Zebrafish gynogenetic half-tetrad diploid clutches carrying mutations were used here. These fish were generated by mutagenizing males with ENU such that their spermatogonia were affected and then mated with females (Solnica-Krezel et al, 1994; Johnson & Zon, 1999) . The F1 female eggs were fertilized in vitro with sperm that had been previously exposed to UV in order to inactivate their DNA. The resulting haploid embryos were treated with high pressure during early embryogenesis to block the second meiotic division and prevent separation of sister chromatids. This procedure converts the haploid embryos to diploids (Beattie et al, 1999) . Thus, F2 progeny carry a number of chemically induced mutations at different loci on paternal chromosomes derived from the original parents (F0). Test crosses of mutagenized males to heterozygous albinos revealed a specific locus mutation rate of 0´002.
Collection of zebrafish blood. For TCA assays, the fish's head was inserted into a slit of a wet sponge to prevent anoxia and the tail fin was clipped with a pair of scissors. The tail was then immersed into a microtitre well of a 96-well dish holding 100 ml of citrate buffer containing 0´63% sodium citrate in phosphate-buffered saline (PBS) without calcium for 1 min to collect blood. After collection, the fish was returned to the water, surviving the procedure. The blood collected was spun in a Sorvall RT-6000 refrigerated centrifuge at 1000 g for 3 min and the plasma was retrieved using a multi-channel pipetter. A small volume (2±5 ml) of this plasma was used to estimate protein concentration by the Bradford assay using the Bio-Rad Protein Assay Dye Reagent. Plasma corresponding to 50 mg of protein was used in the coagulation assay.
For kinetic assays, blood was harvested from adult zebrafish by making an incision in the region of the dorsal aorta and inferior vena cava, just posterior to the dorsal fin (avoiding the gastrointestinal tract) (Jagadeeswaran et al, 1999b) . The zebrafish skin was punctured using a pair of small dissecting scissors in a partially open position, with closure of the blades resulting in a superior lateral incision (,0´2±0´3 cm). Blood welling up from this incision was rapidly collected with a micropipette tip (2 ml of blood from individual fish corresponding to 1 ml of plasma) and injected into 100 ml of citrate buffer. After collecting the blood, the fish was euthanized by keeping it in ice-cold water. Plasma was collected as described above and was used in the kinetic assays as described below.
Preparation of zebrafish muscle thromboplastin. A speciesspecific tissue thromboplastin reagent was prepared from zebrafish muscle as described earlier (Jagadeeswaran & Sheehan, 1999) . Briefly, muscle tissue from zebrafish was suspended in 0´1 mol/l NaCl, 50 mmol/l Tris, pH 7´5, on ice and homogenized with a Brinkman polytron rotor (setting 5) for three 10±15 s intervals, avoiding heating or foaming. This homogenate was stirred at 378C for 30 min and then centrifuged at 11 000 g for 15 min. The supernatant was harvested, EDTA added to produce a concentration of 20 mmol/l and the preparation was centrifuged at 48 000 g for 60 min. The resulting pellet was washed twice by resuspension in 0´1 mol/l NaCl, 50 mmol/l Tris, pH 7´5, and 20 mmol/l EDTA, followed by high-speed centrifugation. The final pellet was resuspended in a minimal volume of buffer without EDTA (1´5±3 ml). The suspension was aliquoted and stored at 2258C for use in the kinetic assays.
Coagulation assays. For TCA assays, plasma corresponding to 50 mg of protein was used to measure coagulation activity by recalcifying the plasma to 33´3 mmol/l final q 2000 Blackwell Science Ltd, British Journal of Haematology 110: 946±956 concentration CaCl 2 in the presence of human fibrinogen (3´3 mg/ml final concentration) and bringing to a final volume of 150 ml with citrate buffer. The visible clot formation was taken as an index of coagulation activity.
Modified coagulation assays were performed in 96-well flat bottomed (VWR, Suwane) microtitre dishes, which were kept on ice. Appropriate amounts (10 ml) of fibrinogen (10 mg/ml) and plasma (0´25 ml for zebrafish and 2´5 ml or 10 ml for human assays) were mixed in each well. Five microlitres of thromboplastin (rabbit brain or zebrafish muscle), actin or (RVV)-Xa (4 ml of 0´33 mg/ml) was added to each well. Each reaction was brought to 94 ml and then recalcified with 6 ml of 100 mmol/l CaCl 2 . The plate was removed from the ice, wiped off thoroughly with a Kimwipe, incubated for 4 min at room temperature and then shaken for 1 min in the HTS BioAssay Reader (Perkin Elmer). The absorbance was recorded every minute for 60 min. When thrombin was generated by the above reagents, the assays were called kinetic prothrombin time (kPT), kinetic partial thromboplastin time (kPTT) and kinetic Russell viper venom activation time (kRVVT) respectively. Negative controls were performed by replacing the clotting reagent with PBS. Screening of approximately 1000 fish from 86 clutches with TCA assay resulted in six clutches (L3, L13, O16, N5, P4 and N13) of fish where a portion of the clutch (mutants) showed prolongation of clot formation compared with normals. The results revealed that the percentages of mutants among these clutches ranged between 30% and 50%. Kinetic curves of fibrin formation in the presence of various doses of actin (A, the doses are 1, 2´5, 5, 10, 20 and 30 ml represented by curves from right to left respectively), rabbit brain thromboplastin (B, the doses are 1, 2´5, 5, 10, 20 and 30 ml represented by curves from right to left respectively), human plasma (C, the doses 2´5, 5, 10 and 20 ml represented by curves from right to left respectively) and human fibrinogen (D, the doses are 0, 0´05, 0´1, 0´15, 0´2, 0´25, 0´3 and 0´35 mg represented by curves from right to left respectively). In all these reactions the final volume was 100 ml. The time in seconds, t [s] , is plotted against absorbance at 405 nm.
RESULTS
Identification of zebrafish mutants with coagulation pathway defects by TCA screening To isolate zebrafish mutants with defects in clotting, we developed a TCA screening assay to measure TCA using small quantities of zebrafish plasma. The principle used in this procedure is to add human fibrinogen and measure fibrin formation by turbidometry. In this assay, a small amount of blood was collected from the zebrafish tail in citrate buffer and a known amount of plasma (protein) was used to assay TCA by adding CaCl 2 . Upon recalcification, fibrin is generated by using all three pathways and, thus, this assay measured total thrombin activity generated from all three coagulation pathways. The formation of fibrin was visually monitored; it took between 5 h and 7 h to obtain a visible clot. This time of visible clot formation was reproducible at a 95% confidence limit. To test whether mutants can be detected by using this assay, we treated zebrafish water with warfarin (0´5 mg/ml of tank water) for 48 h and then warfarinized plasma was used to measure clotting activity. The plasma from warfarin-treated fish produced a visible clot after 15 h. These results suggested that the assay would detect prolongation of clotting and we used this to screen for zebrafish mutants defective in coagulation.
Using the above assay, we screened gynogenetic halftetrad diploid zebrafish. Our screening of approximately 1000 fish from 86 clutches resulted in six clutches of fish where a portion of the clutch showed prolongation of clot formation. The results revealed that the percentages of mutants among these clutches ranged between 30% and 50% ( Table I) .
Development of kinetic assays to characterize the mutants with clotting defects As the above TCA screening assay measured thrombin activity generated by all three pathways, mutants could not be easily characterized. To characterize the above mutants and assign them to respective coagulation pathways, we developed novel kinetic assays, kPT, kPTT and kRVVT, that can measure fibrin-forming activity from extrinsic, intrinsic and common pathways of coagulation respectively. These assays were first validated using human plasma.
Validation of the kinetic assays with human plasmas As it is possible to monitor the kinetics of fibrin formation induced by rabbit brain thromboplastin or actin using 33% of human plasma, by absorbance at 405 nm, we reasoned that use of exogenously added human fibrinogen in dilute plasma should provide sufficient amounts of fibrin when induced by such reagents so that it can be measured by turbidometry (von dem Borne et al, 1995) . However, as such reactions had not been performed earlier using dilute human plasma, we first had to test whether thrombin activity induced by rabbit brain thromboplastin and actin could be monitored as a result of fibrin formation in dilute human plasma in the presence of excess fibrinogen. To this end, we systematically tested the effects of various concentrations of actin, rabbit brain thromboplastin, plasma and fibrinogen in the kinetic assays (kPT and kPTT). The results are shown in Fig 1. With increasing amounts of actin, the rate curve shifted to the left, showing an increase in the rate of fibrin formation (Fig 1A) . Increasing rabbit brain thromboplastin also increased the rate of fibrin formation (Fig 1B) . The results also revealed that increasing the plasma concentrations increased the rates of fibrin formation in the presence of actin (Fig 1C,  kPTT) . With increasing amounts of fibrinogen, the clotting rates were increased both in the presence of actin (Fig 1D,  kPTT) and rabbit brain thromboplastin (data not shown, kPT).
The following data were also obtained for which the rate curves are not shown. With rabbit brain cephalin, rate curves were found to be similar to those found using actin. The above reactions were inhibited by hirudin and heparin in a dose-dependent manner. We also established rates of fibrin formation in presence of RVV-Xa, which measures the common pathway (kRVVT). The effect of TAP, a factor Xa inhibitor that inhibits the common pathway, and CTI, an inhibitor for contact activation that inhibits the intrinsic pathway, were tested in kRVVT and kPTT, and were found to reduce the rates respectively. To demonstrate whether these kinetic assays can be used to detect defects in coagulation pathways, human plasmas with known coagulation factor deficiencies were tested using rabbit brain thromboplastin and actin under these assay conditions (Fig 2) . As predicted, the factor VIIdeficient plasma reactions demonstrated a shift of the curve to the right in kPT reactions, factors VIII-and IXdeficient plasma reactions demonstrated a similar shift in the kPTT reactions, and factors X-and V-deficient plasma reactions showed the shift in both the kPT and kPTT reactions. All these above results established the reproducibility and validity of the kinetic assays.
Evaluation of zebrafish coagulation
To test whether zebrafish plasma could be used to measure rates of thrombin formation, individual zebrafish plasmas were collected as described and the rates were measured in the presence of zebrafish muscle thromboplastin, actin and RVV-Xa. The results showed rate curves comparable to human plasma (Fig 3) . To demonstrate the range of clotting Kinetic curves of fibrin formation in the presence of various doses of warfarin (A and B, kPT and kPTT, respectively, the doses are 0, 0´05, 0´5 and 5 mg/ml of tank water represented by curves from left to right), TAP (C, kRVVT, the doses are 0, 0´03 and 0´05 nmol/l final concentration represented by curves from left to right), low molecular weight heparin (D, the dose is 0´1 mg/ml of tank water) and unfractionated heparin (E, the dose is 1 mg/ml of tank). In D and E, kRVVT, kPTT, and kPT are represented, respectively, from left to right, the left three are normal and the right three are heparin treated. The time in seconds, t [s] , is plotted against absorbance at 405 nm. activity in the zebrafish population, plasma samples from 12 fish were analysed and it was found that the curves in each case fell within a 95% confidence limit (Fig 3) . These data showed that the assay was reproducible and also established the range of coagulation activities in a zebrafish population.
To test whether zebrafish respond to warfarin, an inhibitor of vitamin K-dependent gamma carboxylase that gamma carboxylates the glutamic acids crucial for the function of coagulation factors such as prothrombin, factor VII, factor IX and factor X, fish were placed in water containing different doses of the drug and, after 24 h, plasma was collected and analysed for kPT and kPTT. With increasing amounts of warfarin, there was a prolongation in the kPT and kPTT (Fig 4A and B) . Inhibition of kPT, kPTT and kRVVT were also observed when fish were treated with both low molecular weight and unfractionated heparins (Fig 4D and E) .
To test whether TAP (Fig 4C) , hirudin and CTI (data not shown) inhibit fibrin formation, we added these inhibitors when assaying fibrin formation in zebrafish plasma and found that all inhibited the rates of fibrin formation in their respective pathways. To test whether activating protein C-like activity in zebrafish plasma that might inactivate factor VIII-and V-like activities and, thus, inhibit the fibrin formation, Protac (the purified protein C activator from Agkistrodon contortrix venom) was added to the dilute zebrafish plasma and incubated for 10 min at 378C, prior to incubation with the clotting reagent and recalcification in the kRVVT and kPTT. The incubation of zebrafish plasma with Protac resulted in a decrease in the rates of kRVVT and kPTT (data not shown).
Identification of extrinsic pathway-defective zebrafish
As the above assays have the ability to identify defects in specific pathways, we wanted to test whether screening of zebrafish mutants with these assays would detect defects in the respective pathways. To test whether such a screening would be efficient and practical, we first conducted a largescale screen by analysing 1500 pairs of Florida wild-type zebrafish to detect any naturally occurring mutations and polymorphisms that affect kPT. However, as this assay required sacrifice of the fish, pairs of fish were first bred and then were screened with the kPT assay. This screening resulted in a number of fish that departed from the normal kinetic curve. A representative screening of 48 fish, including some with defective clotting, is shown in Fig 5. To select fish with true kPT defects and to rule out other common pathway defects, we also performed kPTT and kRVVT reactions. We collected about 30 fish which showed abnormal kPT, but had normal kRVVT and kPTT. In Fig 6  we show only the animals that demonstrated kPT defects, but not other pathway defects. Other defects such as intrinsic and common pathway defects were also noted, but the data are not shown here. From the numbers we analysed, it would appear that 1% of wild-type fish carried lower coagulation activities. Furthermore, there were also fish that showed less severe abnormalities (for example see the kPT curves in the first data set at top left and second column third sample down, shown in Fig 6) as compared with other dramatically abnormal kPT curves.
DISCUSSION
In this study, we have identified zebrafish mutants with coagulation defects by measuring fibrin formation using a novel TCA screening assay. In comparison with previously tested procedures, this technique constitutes a practical approach for haemostasis screening of small samples. For example, while the larval bleeding is laborious, the thrombin activity assay measures non-haemostatic functions in addition to blood coagulation. Thus, the assay developed here is a quick and reliable screening tool that directly measures blood coagulation activity in zebrafish plasma and can be used to identify mutations that cause defects in blood coagulation.
In the mutant animals used in this study, it has been shown that the frequency of mutations is 1 in 500 for a single locus mutation. The mutation frequency is high because each fish can carry multiple unrelated mutations. As the coagulation pathway we are dealing with has approximately 12 genes and assuming that an additional 12 genes may be controlling the pathway, one would expect the probability of finding coagulation defects would be 24 times greater because of 24 loci. That would be 24 out of 500, i.e. 5% of the clutches screened should be coagulation factor defective. Our results gave approximately the expected percentages underscoring the power of the screening procedure. Furthermore, as the percentages of mutants we obtained were consistent with the percentages of expected frequencies from mutant half-tetrad studies, they probably constitute mutations induced by ENU.
In zebrafish, mutants are obtained by treating the males with ENU and mating them to normal females. The F1 progeny will then carry paternal mutant alleles and maternal normal alleles. The eggs from F1 females are then fertilized in vitro with UV-treated normal sperm, which is genetically impotent, but has the ability to activate the eggs. Normally, at about the time of ovulation, the eggs complete the first meiotic division and, just before sperm and egg nuclei fuse to form a diploid, finish the second meiotic division. The first meiotic division separates the homologous chromosomes and the second meiotic division separates the sister chromatids. However, when the second meiotic division is beginning to separate sister chromatids, hydrostatic pressure is applied which inhibits this process and breaks down the spindle, preventing separation of chromatids. The resulting diploid set of chromatids derived from maternal origin, therefore called gynogenetic, replicates and separates in the first mitotic division, producing a viable diploid embryo. Thus, if there was a recessive mutation in the F1 female, diploidization should express the phenotype in 50% of the progeny. However, because of recombination between homologous chromosomes in meiosis, which are aligned originally as tetrads, individual sister chromatids that are partly maternal and partly paternal in origin, called half-tetrads, are produced. When the second meiotic division is blocked, the resulting embryo is heterozygous for loci distal to the crossover point and homozygous for loci proximal to this crossover. Thus, these individuals are diploid gynogenetic half-tetrads and, so, reduce the q 2000 Blackwell Science Ltd, British Journal of Haematology 110: 946±956 degree of homozygosity. Therefore, in a given diploid clutch from a single F1 female carrying a recessive mutation, the ratio of diploids to normals may vary and may not follow the strict Mendelian ratio (50:50). Thus, even if 10% of the progeny of a given clutch are mutant diploids, it is still considered that the female carries a recessive mutation. The observed ratio of mutants and normals among the diploids in a given clutch in this report is not inconsistent with the predicted percentages of diploids generated by the early pressure diploidization methods. In addition, the fact that there is more than one mutant in the clutches reported here is suggestive of a heritable recessive trait, although further evaluation is required for confirming phenotypic inheritance.
This paper also describes an approach to characterize mutants by developing novel ultra-sensitive coagulation times (kPT, kPTT and kRVVT) which can be measured from plasma obtained from a single fish. In these assays, other chromogenic and fluorogenic substrates could not be employed as we do not know the substrate specificity of the zebrafish enzymes. In the future, it should be possible to adopt the 384-well format so that even less plasma needs to be used. Similarly, analysis of fibrinogen degradation products (FPA) might even generate more sensitive assays and may offer additional tools to study zebrafish haemostasis.
Validation of the above kinetic assays with human plasmas resulted in the development of microassays that can measure coagulation activities in dilute human plasma.
Demonstration of a shift of the rate curve to the right when using human coagulation factor-deficiency plasmas in comparison with the rate curves obtained with normal human plasma lends credibility to our assays. In this regard, it is important to note that most of the coagulation times used commercially require at least 20±40 ml of plasma. The assay developed here only requires 5 ml of human plasma and it may even be possible to reduce this amount by 10-fold by using 384-well plates, as noted above. Hence, this assay procedure may find some applications in paediatrics. The advantage of the assay for human application is that it uses a natural substrate in contrast to synthetic fluorogenic and chromogenic substrates.
The determination of clotting times by kinetic methods in zebrafish confirms our earlier findings that zebrafish coagulation pathways are conserved and have parallels to mammalian clotting. Coagulation inhibitors such as warfarin and hirudin gave the expected results and confirmed our earlier report that the anticoagulant pathways in zebrafish have similarities to mammalian anticoagulant pathways (Jagadeeswaran et al, 1997; Jagadeeswaran & Sheehan, 1999) . In addition, the observed inhibition of coagulation activity by TAP, a factor X inhibitor, is a new finding and further supports the presence of a factor X-like molecule in zebrafish.
This report also demonstrates the range of coagulation activity in zebrafish and reports identification of coagulation-defective fish in a wild-type population. These observations further established the utility of kinetic assays to screen for mutant coagulation factor genes in the zebrafish model. This study also revealed variations in the coagulation activities in the extrinsic pathway defects, which ranged from severe to barely perceptible abnormalities. The lack of severe abnormalities in coagulation activities in some animals is probably owing to the subtle decreases in factor VII or slight increases in tissue factor pathway inhibitor activity levels. Further studies are required to identify the molecular basis of these variations.
The two methods of screening described in this paper have advantages and disadvantages. Clearly, the TCA screen is an asset because the fish are not sacrificed. However, one disadvantage of this method is that only small amounts of plasma are obtained and only one assay can be performed. Thus, assigning the mutation to the respective pathway must wait until the next generation becomes available. While the kinetic screening method appears to be laborious, only the fish that breed will have to be tested and, thus, reduce labour. However, the parental fish are not available for any back-cross experiments. As the amount of blood collected is several-fold greater, one can perform all three coagulation assays and, thus, the phenotypic defect can be easily assessed much before the progeny. In addition, the selection by the kinetic assay is a more focused screening for selection of specific pathway defects.
In conclusion, this report describes and demonstrates the feasibility of using two novel approaches for the isolation of mutants in coagulation pathways. The identification of these mutants and the ability to classify them will undoubtedly contribute to the isolation of novel genes regulating the haemostasis process. Such new genes may include the genes for novel proteases that are involved in the initial activation of VII, genes for the vitamin K-epoxidereductase system (Cain et al, 1997) , genes controlling the threshold levels of coagulation factors, as well as many more hitherto unidentified genes related to coagulation. In addition, the microassays developed here should also be useful in other situations where a minimal amount of blood is available, such as in paediatric clinics and in analysing haemostasis in small animal models.
